

# Luigi Bolondi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11635736/luigi-bolondi-publications-by-year.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86 papers	19,281 citations	43 h-index	86 g-index
86 ext. papers	22,225 ext. citations	6.9 avg, IF	6.05 L-index

#	Paper	IF	Citations
86	MiR-30e-3p Influences Tumor Phenotype through / Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. <i>Cancer Research</i> , <b>2020</b> , 80, 1720-1734	10.1	27
85	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , <b>2020</b> , 5,	6	21
84	MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	26
83	Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification. <i>Scientific Reports</i> , <b>2019</b> , 9, 14749	4.9	7
82	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 72, 28-36	14.4	163
81	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 681-688	3.3	36
80	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 682-693	21.7	216
79	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. <i>Acta Histochemica</i> , <b>2018</b> , 120, 95-102	2	16
78	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 4	9.8	48
77	From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. <i>Histopathology</i> , <b>2018</b> , 72, 414-422	7.3	4
76	LncRNAs as novel players in hepatocellular carcinoma recurrence. <i>Oncotarget</i> , <b>2018</b> , 9, 35085-35099	3.3	31
75	Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 15350-15364	3.3	59
74	DAAs for HCV and risk of hepatocellular carcinoma: current standpoint. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 736-738	18.8	5
73	Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 54-63	59.2	1015
72	Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e101-e112	21.7	87
71	Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. <i>Scientific Reports</i> , <b>2017</b> , 7, 44685	4.9	10
70	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 173-183	13.4	106

69	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. <i>Hepatic Oncology</i> , <b>2017</b> , 4, 129-137	4	15
68	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. <i>Liver Cancer</i> , <b>2017</b> , 6, 337-348	9.1	13
67	miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 2397-2407	4	12
66	Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis. <i>Internal and Emergency Medicine</i> , <b>2016</b> , 11, 19-30	3.7	9
65	Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 727-733	13.4	612
64	Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. <i>Therapeutic Advances in Gastroenterology</i> , <b>2016</b> , 9, 240-9	4.7	56
63	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 31361-71	3.3	33
62	Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 39609-39626	3.3	21
61	TP53/MicroRNA Interplay in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	22
60	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , <b>2016</b> , 3, 119-136	4	7
59	Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. <i>Molecular Imaging and Biology</i> , <b>2015</b> , 17, 29-37	3.8	43
58	Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 518-22	3.3	46
57	Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , <b>2015</b> , 11, 449-65	3.6	17
56	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1344-54	21.7	553
55	Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. <i>Liver International</i> , <b>2015</b> , 35, 1036-47	7.9	81
54	Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. <i>PLoS ONE</i> , <b>2015</b> , 10, e0141448	3.7	94
53	Contrast-enhanced ultrasound in liver cancer. <i>Hepatic Oncology</i> , <b>2015</b> , 2, 51-62	4	3
52	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1247-56	7.5	88

51	TACE performed in patients with a single nodule of hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2014</b> , 14, 601	4.8	28
50	Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2014</b> , 14, 403	4.8	7
49	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 549-55	3.3	43
48	p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 203-16	6.6	36
47	State of the art: hepatocellular carcinoma. <i>Future Oncology</i> , <b>2014</b> , 10, 1-6	3.6	29
46	Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2014</b> , 5, 10607-20	3.3	37
45	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3412-9	7.5	178
44	Treatment of hepatocellular carcinoma in Child-Pugh B patients. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 852-8	3.3	25
43	Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 712-23	3.3	128
42	Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2013</b> , 4, 1618-31	3.3	40
41	Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. <i>European Journal of Medicinal Chemistry</i> , <b>2012</b> , 48, 391-401	6.8	28
40	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 821-9	13.4	589
39	In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. <i>Journal of Pathology</i> , <b>2012</b> , 227, 275-85	9.4	155
38	Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. <i>Hepatology</i> , <b>2012</b> , 56, 1025-33	11.2	132
37	Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. <i>Seminars in Liver Disease</i> , <b>2012</b> , 32, 348-59	7.3	387
36	Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4397-405	12.9	63
35	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 1015-21	3.3	8
34	From liver cirrhosis to HCC. <i>Internal and Emergency Medicine</i> , <b>2011</b> , 6 Suppl 1, 93-8	3.7	20

33	Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ cm) HCC in cirrhosis. <i>European Radiology</i> , <b>2011</b> , 21, 1233-42	8	152
32	Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine. <i>Tumori</i> , <b>2010</b> , 96, 1028-1030	1.7	11
31	Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2010</b> , 48, 1319-26	5.9	17
30	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. <i>Cancer Research</i> , <b>2010</b> , 70, 5184-93	10.1	347
29	Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 729-34	3.3	9
28	The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42 Suppl 3, S258-63	3.3	46
27	The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 599-609	0.7	151
26	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 391-8	2.2	56
25	Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. <i>Liver Transplantation</i> , <b>2010</b> , 16, 658-67	4.5	70
24	Characterization of focal liver lesions with contrast-enhanced ultrasound. <i>Ultrasound in Medicine and Biology</i> , <b>2010</b> , 36, 531-50	3.5	83
23	MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5073-81	12.9	267
22	MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. <i>Cancer Research</i> , <b>2009</b> , 69, 5761-7	10.1	346
21	Medical treatment of hepatocellular carcinoma. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2009</b> , 1, e2009021	3.2	2
20	MicroRNA involvement in hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , <b>2008</b> , 12, 2189-204	5.6	212
19	Sorafenib in advanced hepatocellular carcinoma. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 378-90	59.2	9089
18	Hepatocellular carcinoma: epidemiology and clinical aspects. <i>Molecular Aspects of Medicine</i> , <b>2008</b> , 29, 130-43	16.7	78
17	Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2008</b> , 48, 848-57	13.4	93
16	Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. <i>BMC Cancer</i> , <b>2007</b> , 7, 171	4.8	41

15	Recent advances in the diagnosis of hepatocellular carcinoma. <i>Hepatology Research</i> , <b>2007</b> , 37 Suppl 2, S178-92	5.1	15
14	Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. <i>Cancer Research</i> , <b>2007</b> , 67, 6092-9	10.1	695
13	The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. <i>Ultrasound in Medicine and Biology</i> , <b>2006</b> , 32, 1369-75	3.5	526
12	Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 310-6	13.4	38
11	Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. <i>Hepatology</i> , <b>2005</b> , 42, 27-34	11.2	356
10	Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 421-6	13.4	104
9	Liver metastases from rectal carcinoma: disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy. <i>Journal of Clinical Ultrasound</i> , <b>2003</b> , 31, 387-91	1	12
8	Screening for hepatocellular carcinoma in cirrhosis. <i>Journal of Hepatology</i> , <b>2003</b> , 39, 1076-84	13.4	153
7	Assessment of vascular patterns of small liver mass lesions: value and limitation of the different Doppler ultrasound modalities. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 3537-46	0.7	35
6	In hepatocellular carcinoma AgNOR protein expression correlates with tumour mass doubling time. <i>Journal of Hepatology</i> , <b>1996</b> , 24, 60-5	13.4	17
5	Enzymatic cytochemistry, DNA ploidy and AgNOR quantitation in hepatocellular nodules of uncertain malignant potential in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , <b>1996</b> , 41, 800-8	4	8
4	Diagnostic and prognostic value of DNA ploidy and cell nuclearity in ultrasound-guided liver biopsies. <i>Cancer</i> , <b>1994</b> , 74, 1713-9	6.4	19
3	Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. <i>Hepatology</i> , <b>1992</b> , 16, 132-7	11.2	342
2	Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. <i>Cancer</i> , <b>1992</b> , 69, 925-9	6.4	356
1	Imaging of the Liver500-548		